Inclusion Criteria:

1. Pathological diagnosis in patients with non-small cell lung cancer

2. Patients ≥ 18 years of age;

3. pathological diagnosis of non-small cell lung cancer and lung primary tumor for EGFR
mutation detection method ARMs;

4. enhanced MRI showed brain metastases ≥ 2 or resection of brain metastases from NSCLC
presence of residual lesions ≥ 2 / intracranial metastases in patients with
new-onset.

5. Accept WBRT concurrent disabled erlotinib treatment Iressa ≥ 14 days;

6. Expected survival ≥ 3 months;

7. KPS score ≥ 70;

8. GPA score 0.5-4;

9. week before randomization, patients with bone marrow and liver and kidney function
meet the following criteria:

① hemoglobin ≥ 10 g / L, neutrophils ≥ 1.5 × 109 / L and platelets ≥ 10 × 109 / L;

② total bilirubin ≤ 1.0 times upper limit of normal, aspartate aminotransferase (AST)
and alanine aminotransferase (ALT) ≤ 1.5 times upper limit of normal;

③ creatinine ≤ 15mg / L, urea nitrogen ≤ 200mg / L;

10. able to understand and sign the informed consent.-

Exclusion Criteria:

1. patient had received brain radiotherapy;

2. there is a significant uncontrolled diseases such as AIDS, neurological / mental
illness such as Alzheimer's disease;

3. pregnant or lactating women; fertile without taking adequate contraceptive measures
are;

4.4 weeks before enrollment received any other investigational drug;

5.There is a history of immune deficiency, or suffering from other acquired, congenital
immunodeficiency disease, or history of organ transplantation;

6.According to the researchers judged serious harm or affect patient safety comorbidity in
patients who completed the study.